Saturday, June 27, 2020 10:39:13 PM
I have a few questions?
Do you believe that the last 31-32 patients are all treatment patients?
If your answer is “Yes”, do you agree that there are about 25 placebo patients in the last group of 108 patients? (first 223 patients randomized 2:1 = 149 treatment and 74 placebo. 99-74 = 25)
Do you agree that the last group of placebo patients may have received better surgical treatment than the first 74 placebo patients? (ALA-5 in Europe …etc.!)
Do you agree that at least 60% of placebo patients in this trial are dead after 22 months?
If your answer is “Yes”, at least 15 out of 25 placebos of the last group of 108 are dead and no more than 10 placebo patients are still alive at the time of the interim analysis. That was mid-March 2017 = 22 months after surgery of the last placebo patient (around mid-May 2015.)
Next question:
Do you belong to the group of ihub members who are convinced that the number of cross-over placebo patients increased from 54 to 66 cross-over placebo patients between mid-March 2017 ( interim analysis) and end of May 2017 (Asco 2017)? (From 86.4% to 90% of the ITT group) That is an increase of 12 cross-over placebo patients.
If your answer is “Yes”, I assume that you can only conclude that all placebo patients censored between month 22 and month 36 on the OS curve were progression free at the time of the interim analysis(WOW!!) and all these placebo patients(increase of 12) got recurrence from their brain tumour between mid-March 2017 and the end of May 2017. (10 placebo patients censored between month 22 and month 30 and about 2 out of 7 patients censored between month 30 and month 36 on the OS curve March 2017). Unbelievable!!
Conclusion: Do you agree that none of the last 25 placebo patients (the best group=ALA-5 surgery...etc.) were progression free 36 months after surgery if the above is correct ?
Last question:
If none of the last 25 patients were progression free 36 months after surgery, why do you believe that 8 of the first 74 placebo patients were progression free 36 months after surgery?
NOTE: 86.4% of the ITT population received the experimental DC treatment at some point during the trial at the time of the interim analysis March 2017.( https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6)
I believe that number of 86.4% never changed after March 2017.
OS curve March 2017:
https://investorshub.advfn.com/uimage/uploads/2018/10/22/gddzjCombined_charts_no_notes_revised_-lykiri.jpg
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM